NDAORALCAPSULEPriority Review
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
RET. In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, and decreased tumor cell viability in multiple cell lines harboring ALK fusions, amplifications, or activating mutations. The major active metabolite…
Indications (2)
Clinical Trials (1)
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Started Apr 2014
673 enrolled
NeoplasmsSolid TumorsBiliary Cancer+2 more
Loss of Exclusivity
LOE Date
Apr 24, 2035
111 months away
Patent Expiry
Apr 24, 2035
Exclusivity Expiry
Apr 18, 2031